Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Parathyroid Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Hyperparathyroidism, Primary 1

Interventions

Cisplatin 38Radiotherapy 35Magnetic Resonance Spectroscopy 32Specimen Handling 22Cetuximab 18Fluorouracil 17Radiotherapy, Intensity-Modulated 16Platinum 161,2-diaminocyclohexaneplatinum II citrate 16Biopsy 15Paclitaxel 13Carboplatin 13Nivolumab 11Docetaxel 10pembrolizumab 8Radiation 8Fluorodeoxyglucose F18 8Erlotinib Hydrochloride 8Bortezomib 8Bevacizumab 8Gemcitabine 7Sorafenib 6Immunoglobulin G 6Disulfides 6aldesleukin 5Hydroxyurea 5Gefitinib 5Chemotherapy, Adjuvant 5(225)Ac-DOTA-c(RGDyK) 5cabozantinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × fluorocholine × Head & Neck × Clear all
NCT07444723 2026-05-12

Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors

National Institutes of Health Clinical Center (CC)

Phase 2/3 Recruiting
193 enrolled
EndocrineHead & Neck

Parathyroid Neoplasms, Multiple Endocrine Neoplasia Type 1, Hyperparathyroidism, Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡